MREO - Mereo BioPharma +8% on rare pediatric disease designation to Setrusumab

U.S. Food and Drug Administration grants Mereo BioPharma (MREO) +8% rare pediatric disease designation to setrusumab for the treatment of osteogenesis imperfecta.Setrusumab is a fully humanized monoclonal antibody that inhibits sclerostin, a protein which inhibits the activity of bone-forming cells.steogenesis imperfecta is a genetic rare disorder with no approved treatments that is characterized by reduced bone mass and fragile bones that break easily. In Mereo’s Phase 2b ASTEROID study, setrusumab demonstrated a dose-dependent bone building effect and a trend of reduction in fractures in addition to being safe and well tolerated in adults with OI. Source: Press Release

For further details see:

Mereo BioPharma +8% on rare pediatric disease designation to Setrusumab